Amarin Corp Plc (AMRN)

[Hamoa]

Pay-to-delay agreements, where a generic is paid to stay out of a market they have rights to enter, are largely prohibited. When the generics prevailed in court, they won those rights.

I would agree that there are lots of stumbling blocks for other generics to enter the market, so I’m not concerned about a stampede of other competitors.
I think the likely universe of Vascepa and generic Vascepa marketers will be limited to Amarin/Hikma/Reddys/Teva.